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Purpose: Antigen (Ag)-presenting cells (APCs) participate in the development of allergic conjunctivitis (AC). However,
the conjunctival APCs that take up Ag in AC have not been identified. We sought to clarify the phenotypes of conjunctival
APCs that take up, process, and present Ag to T cells during the development of experimental AC.
Methods: Splenocytes from naïve ovalbumin (OVA)-specific T cell receptor transgenic (DO11.10) mice were stimulated
with  either  OVA,  gold,  or  OVA-gold  to  evaluate  stimulation-induced  proliferation.  Naïve  DO11.10  mice  were
subconjunctivally injected with PBS, gold, or OVA-gold. Twenty-four hours later, conjunctivas were harvested for
immunohistochemistry and electron microscopy to identify cells that engulfed OVA-gold.
Results: Stimulation of DO11.10 splenocytes with OVA-gold but not gold alone induced similar levels of proliferation
as OVA alone. Subconjunctival injection of OVA-gold, but not gold alone, induced infiltration of eosinophils and CD4-
positive T cells into the conjunctiva.  The  cells  that  took  up  OVA-gold  into  their  cytoplasma  expressed  Cluster  of
Differentiation (CD) 11b, CD68, major histocompatibility complex (MHC) class II.
Conclusions: It appears that conjunctival macrophages are APCs in the development of experimental AC.
Allergic conjunctivitis (AC) is mediated by activation of
mast cells and the released chemical mediators [1]. These
mediators are capable of inducing infiltration of inflammatory
cells into the conjunctiva. We demonstrated that antigen (Ag)-
specific immunoglobulin (Ig) E -mediated mast cell activation
in the conjunctiva is not able to induce severe conjunctival
infiltration of eosinophils [2], a hallmark of severe forms of
AC [3]. In contrast, transfer of Ag-specific T helper type 2
(Th2) cells into syngeneic mice followed by Ag challenge in
the conjunctiva induced significant infiltration of eosinophils
[4]. Thus, it appears that Th2 cells rather than mast cells play
an  important  role  in  conjunctival  eosinophilia  during  the
development of experimental AC (EC).
For  Th2  cell  activation,  Ag-presenting  cells  (APCs)
present Ag peptides in the context of major histocompatibility
complex (MHC) class II [5]. In AC, Ag challenge occurs in
the conjunctiva, and the Ag must be captured by conjunctival
APCs. We previously investigated the identity of conjunctival
APCs during the development of EC by using Brown Norway
rats [6]. In that report, we were not able to confirm which
conjunctival APCs take up and process the Ag due to the
limited availability of reagents in this system. Therefore, in
this study, we sought to clarify the phenotypes of conjunctival
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APCs that take up and process Ag by using the Ag conjugated
with gold as a marker.
METHODS
Mice: αβ-T cell receptor (TcR)-transgenic BALB/c DO11.10
mice [7], which are transgenic for the TcR specific for the
immunodominant epitope of ovalbumin (OVA; peptide 323–
339),  were  kindly  provided  by  Dr.  Iwabuchi  (Hokkaido
University, Japan). They were bred in a specific pathogen-free
animal facility in Kochi Medical School. Animals between 6
and 12 weeks of age were used for the experiments. All animal
procedures conformed to the ARVO Resolution on Use of
Animals in Research.
Reagents: OVA (grade V) was purchased from Seikagaku
Co.,Tokyo, Japan. Gold (diameter: 15 nm) was purchased
from BB International (Cardiff, UK). Anti-mouse Cluster of
Differentiation  11b  (CD11b)  (Invitrogen  Corp,  Carlsbad,
CA), anti-mouse Cluster of Differentiation 4 (CD4), anti-
mouse Cluster of Differentiation 68 (CD68), and anti-MHC
class II (BD Biosciences PharMingen, San Diego, CA) were
purchased, and rabbit anti-mouse major basic protein (MBP)
was  kindly  provided  by  Dr.  James  J.  Lee  (Mayo  Clinic,
Scottsdale,  AZ).  Biotinylated  rabbit  polyclonal  anti-rat
immunoglobulins  (Dako  Cytomation,  Glostrup,  Denmark)
and biotinylated goat polyclonal anti-rabbit immunoglobulins
(BD  Biosciences  PharMingen)  were  used  as  secondary
antibodies (Abs).
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1280Preparation of OVA-gold: To conjugate OVA to gold, 18 ml
of gold colloid was reacted with 720 μg OVA. The suspension
was then centrifuged, and the supernatant was discarded. The
final concentration of OVA in the OVA-gold conjugate was
calculated to be 1.67 mg/ml. The number of gold particles was
5×1012 per ml. These procedures were conducted in Operon
Biotechnologies Japan, Tokyo, Japan.
Cellular  proliferation  assay:  3×105  splenocytes/well  from
naïve DO11.10 mice were cultured with 1, 10, and 100 μg/ml
of OVA in 96-well flat-bottom plates in a final volume of
0.2 ml RPMI 1640 medium supplemented with 5% fetal calf
serum  (FCS)  and  2-mercaptoethanol  (2-ME).  As  a
background control, OVA, gold, and OVA-gold were omitted
from the well. OVA-gold was added to the culture at OVA
concentrations of 1, 10, and 100 μg/ml. Gold alone was added
to the culture so that the wells contained the same amount of
gold as the OVA-gold wells. After incubation for 48 h at 37 °C
in  a  humidified  atmosphere  with  5%  CO2,  cultures  were
pulsed for 16 h with 0.5 μCi/well of [3H]thymidine (Japan
Atomic Energy Research Institute, Tokai, Japan). The cultures
were then harvested and the radioactivity was measured by
standard techniques. Data were expressed as mean cpm+/
−SD.
Immunohistochemistry:  DO11.10  mice  were
subconjunctivally injected wtih PBS, gold or OVA-gold (n=4
mice per group). The mice were injected with 10 μl of OVA-
gold containing 16.7 μg of OVA and 5×109 gold particles.
When gold alone was administered, mice were injected with
the same amount of gold that was present in the OVA-gold
injections. Twenty-four hours later, the conjunctivas were
harvested, embedded in Optimal Cutting Temperature (OCT)
compound (VWR, Suwanee, GA) and snap frozen in liquid
nitrogen. Vertical 4-μm sections were prepared and fixed in
methanol. Endogenous peroxidase activity was inhibited by
incubation with 0.1% NaN3 and 0.3% H2O2 in distilled water
for 10 min at room temperature. The samples were exposed
to the anti-MBP, anti-CD4, anti-CD11b, or anti-CD68 Abs for
30 min and then to the appropriate biotinylated secondary Ab
for another 30 min. As a control, the samples were exposed to
biotinylated rabbit polyclonal anti-rat immunoglobulins but
not to any first Abs. Ab binding was revealed by using an
Avidin-Biotin-Complex  kit  (Vector  Laboratories  Inc.,
Burlingame,  CA)  followed  by  development  with  3,3′-
diaminobenzidine tetrahydrochloride (Sigma, St. Louis, MO).
Transmission electron microscopy: The conjunctivas were
harvested  and  fixed  in  2.5%  glutaraldehyde,  2.0%
paraformaldehyde,  and  0.1  M  phosphate  buffer  (pH  7.2),
immersed in 1% OsO4 for 1 h at 4 °C, stained en bloc with
2.0%  uranyl  acetate  for  30  min,  dehydrated  by  graded
concentrations of ethanol, and embedded in Spurr's resin. Thin
sections  (90  nm)  were  generated  and  stained  with  either
methylene blue-azure II-basic fuchsin [8] or uranyl acetate
and lead citrate to examine under light microscope or electron
microscope (H7100; Hitachi, Tokyo, Japan), respectively.
Statistical Analysis: Because the infiltrating cell number data
and the proliferation assay data showed approximately normal
distribution (data not shown), the parametric test was applied
for statistical analysis. P values <0.05 were considered to be
significant.
RESULTS
OVA-gold stimulates splenocytes from DO11.10 mice: To
examine  whether  OVA-gold  has  antigenicity,  splenocytes
from naïve DO11.10 mice were stimulated in vitro with OVA-
Figure 1. In vitro antigenicity of OVA-
gold. Splenocytes from naïve DO11.10
mice were cultured in vitro with OVA,
gold,  or  OVA-gold.  OVA-gold  was
added to the culture at a concentration
of 1, 10, and 100 μg/ml of OVA . Gold
alone was added to the culture so that the
same amount of gold per well was added
as in the OVA-gold wells. Proliferation
was  evaluated  by  [3H]thymidine
incorporation. Background cpm (no Ag)
was  1707+/−290.  One  representative
data of two experiments is shown. The
double  asterisk  indicates  a  p<0.01
compared to the background.
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1281gold. As controls, these splenocytes were stimulated with
either OVA alone or gold alone. Similar to when splenocytes
were  stimulated  with  OVA  alone,  OVA-gold  induced
significant  proliferation  of  splenocytes  both  at  10  and
100 μg/ml (Figure 1). For OVA-gold stimulation, as the OVA
concentration in vitro increases, amount of gold in each well
also increases. To examine whether the amount of gold affects
splenocyte  proliferation,  we  added  gold  alone  at  a  level
identical  to  that  in  OVA-gold  at  three  different  OVA
concentrations (1, 10, 100 μg/ml). Regardless of the amount
of gold added to the well, gold alone did not significantly
induce splenocyte proliferation (Figure 1).
Subconjunctival injection of OVA-gold induces conjunctival
inflammation: Next, we investigated whether OVA-gold has
antigenicity in vivo. To this end, OVA-gold was injected into
the subconjunctival space of DO11.10 mice. Subconjunctival
Figure 2. Effect of subconjunctival injection of OVA-gold in the conjunctiva. OVA-gold, gold or PBS (10 μl) was injected into the
subconjunctival space of DO11.10 mice. Twenty-four hours later, conjunctivas were collected for immunohistochemical analyses. MBP-
positive eosinophils and CD4-positive T cells were detected in the OVA-gold-injected group (A). Control samples were not stained with any
primary antibodies. MBP-positive eosinophils were quantified in the OVA-gold and control groups (B). The double asterisk indicates a p<0.01
compared to PBS and the gold groups.
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1282injection of OVA-gold induced an influx of inflammatory
cells in the conjunctiva and immunohistochemical analysis of
conjunctival  infiltrating  cells  revealed  that  MBP-positive
eosinophils  and  CD4-positive  T  cells  infiltrated  into  the
conjunctiva  of  OVA-gold-injected  mice  (Figure  2A).
Subconjunctival injection of gold alone or PBS did not induce
apparent inflammation in the conjunctiva (data not shown).
Counting  of  MBP-positive  eosinophils  revealed  that
significantly  more  eosinophils  were  detected  in  the
conjunctiva of the OVA-gold-injected group compared to the
gold alone- or PBS-injected groups (Figure 2B). These results
indicate that OVA-gold has antigenicity in vivo as well as in
vitro.
Figure 3. Examination of cells that engulfed OVA-gold in the conjunctiva. Conjunctival samples were prepared as described in Figure 2. Cells
that engulfed OVA-gold were examined histologically by light (A) and electron microscopy (B). Gold particles were detected in the cytoplasma
of cells in the conjunctiva (A). C and R indicates conjunctiva and retina, respectively (A). Gold particles were present in cytoplasms of oval-
shaped cells and spindle-like-shaped cells (B). Arrows indicate cells that engulfed gold particles.
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1283Subconjunctivally injected OVA-gold exists in the cytoplasma
of cells in the conjuncitva: The above findings suggest that
OVA-gold  was  engulfed  by  cells  in  the  conjunctiva,  and
antigenic epitopes were presented to OVA-specific T cells. To
examine this directly, conjunctivas were harvested 24 h after
subconjunctival injection of OVA-gold. These conjunctivas
were subjected to histological analysis by using either a light
microscope  or  an  electron  microscope.  Light  microscopic
analysis demonstrated that gold particles were detected in the
cytoplasm  of  cells  in  the  conjunctiva  (Figure  3A).  Gold
particles were also detected in the extracelluar matrix spaces
(data not shown). Electron microscopic analysis revealed that
gold  particles  were  present  and  had  accumulated  in  the
cytoplasm of oval-shaped cells and spindle-like-shaped cells
(Figure 3B).
Cells  engulfed  OVA-gold  express  macrophage  surface
markers: To further characterize the phenotypes of the cells
that  took  up  OVA-gold,  harvested  conjunctivas  were
subjected  to  immunohistochemical  analysis.  Cells  that
engulfed OVA-gold express CD11b, CD68, and MHC class
II molecules (Figure 4).
DISCUSSION
Although  there  have  been  several  reports  [9-13]  that
investigated  APCs  in  the  conjunctiva  of  AC  patients  and
animals, none confirmed which cell types take up the Ag and
present antigenic peptides to T cells. Using gold as a marker,
we sought to identify the conjunctival APCs that play a crucial
role in the development of AC.
We found that after subconjunctival injection of OVA-
gold, CD11b- and CD68-positive cells in the conjunctiva took
up the conjugated particles. Importantly, MHC class II was
expressed in the cells that engulfed OVA-gold. Thus, MHC
class II-expressing macrophages are likely to be the APCs in
the conjunctiva.
The uptake of OVA-gold by conjunctival macrophages
does  not  guarantee  that  the  macrophages  that  took  it  up
express antigenic peptides to T cells. To examine this issue,
we initially investigated the antigenicity of OVA-gold using
DO11.10 splenocytes which contain OVA 323–339-specific
T cells. OVA-gold, as well as OVA, induced proliferation of
splenocytes in a dose-dependent manner, while gold alone did
not.  Thus,  it  was  confirmed  that  OVA-gold  has  similar
antigenicity to OVA. Next, we investigated antigenicity in
vivo by injecting OVA-gold subconjunctivally into DO11.10
mice. OVA-gold, but not gold alone, induced conjunctival
eosinophilia  to  a  similar  severity  as  resulted  from
subconjunctival injection with OVA alone. Thus, it appears
that OVA-gold is antigenic both in vitro and in vivo. Together
with the fact that the OVA-gold-engulfing, CD68-positive
macrophages also express MHC class II molecules, these data
show that this cell population indeed functions as an APC in
the conjunctiva during the development of EC.
To investigate the role of conjunctival macrophages in
conjunctival  eosinophilia,  clodronate  liposomes  [14]  were
injected into the conjunctiva of DO11.10 mice. Seventy-two
hours later when conjunctival macrophages were depleted,
OVA-gold  was  subconjunctivally  injected  and  24  h  later,
conjunctivas  were  collected  for  immunohistochemical
analysis  to  detect  eosinophils.  Conjunctival  eosinophil
numbers  were  not  different  between  mice  that  received
clodronate liposomes and PBS as a control (data not shown).
This result suggests that not only macrophages but also other
types  of  cells  such  as  dendritic  cells  are  APC  in  the
conjunctiva. Another possibility is depletion of conjunctival
macrophages is not complete as previously reported [15] and
therefore,  residual  macrophages  uptake  OVA-gold  and
present the Ag to T cells.
It is possible that a certain type of APC may not be able
to uptake a large particle such as gold. It is also possible that
some types of APCs can take up OVA, but not OVA-gold.
Although  CD68-positive  macrophages  were  identified  as
APCs in the conjunctiva during the development of EC in this
study, other types of APC may also play a role, as discussed
above. In the future, the use of small molecules rather than
gold will aid in clarifying the role of dendritic cells in the
Figure 4. Phenotypic characterization of cells that engulfed OVA-gold in the conjunctiva. Conjunctival samples were prepared as described
in Figure 2. Samples were evaluated immunohistochemically to examine the expression of CD11b, CD68, and MHC class II.
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1284development of EC. Furthermore, our data support the idea
that APC-targeted therapy may be useful for the prevention
of AC, since dysfunction of conjunctival APCs attenuates T
cell activation in the conjunctiva.
ACKNOWLEDGMENTS
We would like to acknowledge Ms. Zhou Pingping for her
technical help. This work was supported in part by Grant-in-
Aid for Scientific Research from the Ministry of Education,
Culture, Sports, Science, and Technology, Japan. (A.F.).
REFERENCES
1. Trocme SD, Sra KK. Spectrum of ocular allergy. Curr Opin
Allergy Clin Immunol 2002; 2:423-7. [PMID: 12582327]
2. Fukushima A, Ozaki A, Jian Z, Ishida W, Fukata K, Ueno H,
Liu FT. Dissection of antigen-specific humoral and cellular
immune  responses  for  the  development  of  experimental
immune-mediated blepharoconjunctivitis in C57BL/6 mice.
Curr Eye Res 2005; 30:241-8. [PMID: 15823916]
3. Fukagawa K, Nakajima T, Tsubota K, Shimmura S, Saito H,
Hirai K. Presence of eotaxin in tears of patients with atopic
keratoconjunctivitis with severe corneal damage. J Allergy
Clin Immunol 1999; 103:1220-1. [PMID: 10359913]
4. Ozaki A, Seki Y, Fukushima A, Kubo M. The control of allergic
conjunctivitis by suppressor of cytokine signaling (SOCS)3
and  SOCS5  in  a  murine  model.  J  Immunol  2005;
175:5489-97. [PMID: 16210657]
5. Germain RN. MHC-dependent antigen processing and peptide
presentation: providing ligands for T lymphocyte activation.
Cell 1994; 76:287-99. [PMID: 8293464]
6. Ozaki  A,  Fukushima  A,  Ishida  W,  Zinchuk  O,  Fukata  K,
Hayashi Y, Enzan H, Takata M, Yagita H, Ueno H. Analysis
of  Ag-presenting  cells  in  the  conjunctiva  during  the
development  of  experimental  immune-mediated
blepharoconjunctivitis.  Curr  Eye  Res  2004;  29:277-86.
[PMID: 15590473]
7. Murphy KM, Heimberger AB, Loh DY. Induction by antigen
of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in
vivo. Science 1990; 250:1720-3. [PMID: 2125367]
8. Humphrey CD, Pittman FE. A simple methylene blue-azure II-
basic fuchsin stain for epoxy-embedded tissue sections. Stain
Technol 1974; 49:9-14. [PMID: 4131626]
9. Abu el-Asrar AM, Geboes K, Tabbara KF, van den Oord JJ,
Missotten  L.  Immunopathogenesis  of  vernal
keratoconjunctivitis.  Bull  Soc  Belge  Ophtalmol  1996;
261:15-24. [PMID: 9009358]
10. Choi TH, Ko MK, Choe JK. Increased numbers of Langerhans
cell and expression of HLA-Dr antigen in the giant papilla of
patients  with  giant  papillary  conjunctivitis.  Korean  J
Ophthalmol 1996; 10:18-23. [PMID: 8755197]
11. Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic
characterization  of  T  cells  infiltrating  the  conjunctiva  in
chronic allergic eye disease. J Allergy Clin Immunol 1996;
98:686-96. [PMID: 8828547]
12. Abu-El-Asrar AM, Al-Kharashi SA, Al-Mansouri S, Missotten
L, Geboes K. Langerhans' cells in vernal keratoconjunctivitis
express the costimulatory molecule B7–2 (CD86), but not
B7–1  (CD80).  Eye  (Lond)  2001;  15:648-54.  [PMID:
11702979]
13. Ohbayashi  M,  Manzouri  B,  Flynn  T,  Toda  M,  Ikeda  Y,
Nakamura  T,  Ono  SJ.  Dynamic  changes  in  conjunctival
dendritic cell numbers, anatomical position and phenotype
during experimental allergic conjunctivitis. Exp Mol Pathol
2007; 83:216-23. [PMID: 17560570]
14. Van Rooijen N, Sanders A. Liposome mediated depletion of
macrophages: mechanism of action, preparation of liposomes
and  applications.  J  Immunol  Methods  1994;  174:83-93.
[PMID: 8083541]
15. Fukushima A, Ozaki A, Ishida W, van Rooijen N, Fukata K,
Ueno  H.  Suppression  of  macrophage  infiltration  into  the
conjunctiva  by  clodronate  liposomes  in  experimental
immune-mediated blepharoconjunctivitis. Cell Biol Int 2005;
29:277-86. [PMID: 15893479]
Molecular Vision 2010; 16:1280-1285 <http://www.molvis.org/molvis/v16/a141> © 2010 Molecular Vision
The print version of this article was created on 7 July 2010. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1285